The first such evidence was provided by Teo et al. (2010), who demonstrated that RAP1 can translocate to the cytoplasm and that, independently of TRF2, it acts as a modulator of NF-κB signaling pathway, thus affecting NF-kB activity, which also has an important role in cancer. This evidence concerns the gene NFKB1 and cancer.